Which has preferable valuation & earnings, LNTH or PEN?

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.55B 4.46 $233.56M $4.15 25.55 Penumbra $1.40B 8.91 $177.69M $4.34 73.29

Is LNTH or PEN more profitable?

Lantheus has a net margin of 18.05% compared to Penumbra's net margin of 11.76%. Lantheus' return on equity of 29.32% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Penumbra 11.76% 10.87% 8.45%

Does the media refer more to LNTH or PEN?

In the previous week, Lantheus had 2 more articles in the media than Penumbra. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Penumbra. Penumbra's average media sentiment score of 0.68 beat Lantheus' score of 0.46 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PEN or ITGR?

Penumbra has higher earnings, but lower revenue than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.91 $177.69M $4.34 73.29 Integer $1.86B 1.64 $102.81M $4.01 22.31

Is PEN or ITGR more profitable?

Penumbra has a net margin of 11.76% compared to Integer's net margin of 7.64%. Integer's return on equity of 12.83% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 11.76% 10.87% 8.45% Integer 7.64% 12.83% 6.51%

Which has stronger earnings and valuation, MDLN or PEN?

Medline has higher revenue and earnings than Penumbra. Penumbra is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medline $29.14B 1.59 $1.16B $0.32 110.31 Penumbra $1.40B 8.91 $177.69M $4.34 73.29

Is MDLN or PEN more profitable?

Penumbra has a net margin of 11.76% compared to Medline's net margin of 0.00%. Penumbra's return on equity of 10.87% beat Medline's return on equity. Company Net Margins Return on Equity Return on Assets Medline N/A N/A N/A Penumbra 11.76% 10.87% 8.45%

Does the media favor MDLN or PEN?

In the previous week, Medline had 15 more articles in the media than Penumbra. MarketBeat recorded 17 mentions for Medline and 2 mentions for Penumbra. Penumbra's average media sentiment score of 0.68 beat Medline's score of 0.15 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 2 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GEHC or PEN?

In the previous week, GE HealthCare Technologies had 7 more articles in the media than Penumbra. MarketBeat recorded 9 mentions for GE HealthCare Technologies and 2 mentions for Penumbra. GE HealthCare Technologies' average media sentiment score of 1.36 beat Penumbra's score of 0.68 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PHG or PEN?

Penumbra has a consensus target price of $361.33, suggesting a potential upside of 13.60%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Penumbra 0 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18

Does the media favor PHG or PEN?

In the previous week, Koninklijke Philips and Koninklijke Philips both had 2 articles in the media. Penumbra's average media sentiment score of 0.68 beat Koninklijke Philips' score of 0.50 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Penumbra (PEN) Competitors

$318.08 +1.88 (+0.59%)

As of 03:58 PM Eastern

Compare

PEN vs. LNTH, ITGR, MDLN, GEHC, and PHG

Should you buy Penumbra stock or one of its competitors? MarketBeat compares Penumbra with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Penumbra include Lantheus (LNTH), Integer (ITGR), Medline (MDLN), GE HealthCare Technologies (GEHC), and Koninklijke Philips (PHG).

How does Penumbra compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Penumbra (NYSE:PEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Lantheus has a net margin of 18.05% compared to Penumbra's net margin of 11.76%. Lantheus' return on equity of 29.32% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Penumbra	11.76%	10.87%	8.45%

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market.

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.46	$233.56M	$4.15	25.55
Penumbra	$1.40B	8.91	$177.69M	$4.34	73.29

99.1% of Lantheus shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 2.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lantheus currently has a consensus price target of $101.86, suggesting a potential downside of 3.94%. Penumbra has a consensus price target of $361.33, suggesting a potential upside of 13.60%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

In the previous week, Lantheus had 2 more articles in the media than Penumbra. MarketBeat recorded 4 mentions for Lantheus and 2 mentions for Penumbra. Penumbra's average media sentiment score of 0.68 beat Lantheus' score of 0.46 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Penumbra on 9 of the 16 factors compared between the two stocks.

How does Penumbra compare to Integer?

Penumbra (NYSE:PEN) and Integer (NYSE:ITGR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Penumbra has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Integer has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Penumbra has a net margin of 11.76% compared to Integer's net margin of 7.64%. Integer's return on equity of 12.83% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Integer	7.64%	12.83%	6.51%

Penumbra presently has a consensus price target of $361.33, indicating a potential upside of 13.60%. Integer has a consensus price target of $98.71, indicating a potential upside of 10.36%. Given Penumbra's higher probable upside, research analysts plainly believe Penumbra is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Penumbra has higher earnings, but lower revenue than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.91	$177.69M	$4.34	73.29
Integer	$1.86B	1.64	$102.81M	$4.01	22.31

88.9% of Penumbra shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 1.1% of Integer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Penumbra had 2 more articles in the media than Integer. MarketBeat recorded 2 mentions for Penumbra and 0 mentions for Integer. Penumbra's average media sentiment score of 0.68 beat Integer's score of 0.00 indicating that Penumbra is being referred to more favorably in the media.

Company	Overall Sentiment
Penumbra	Positive
Integer	Neutral

Summary

Penumbra beats Integer on 11 of the 16 factors compared between the two stocks.

How does Penumbra compare to Medline?

Medline (NASDAQ:MDLN) and Penumbra (NYSE:PEN) are both large-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Penumbra has a net margin of 11.76% compared to Medline's net margin of 0.00%. Penumbra's return on equity of 10.87% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Penumbra	11.76%	10.87%	8.45%

Medline currently has a consensus price target of $50.54, indicating a potential upside of 43.17%. Penumbra has a consensus price target of $361.33, indicating a potential upside of 13.60%. Given Medline's stronger consensus rating and higher probable upside, research analysts clearly believe Medline is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

In the previous week, Medline had 15 more articles in the media than Penumbra. MarketBeat recorded 17 mentions for Medline and 2 mentions for Penumbra. Penumbra's average media sentiment score of 0.68 beat Medline's score of 0.15 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	2 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Penumbra shares are held by institutional investors. 0.8% of Medline shares are held by company insiders. Comparatively, 2.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Medline has higher revenue and earnings than Penumbra. Penumbra is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$29.14B	1.59	$1.16B	$0.32	110.31
Penumbra	$1.40B	8.91	$177.69M	$4.34	73.29

Summary

Medline and Penumbra tied by winning 8 of the 16 factors compared between the two stocks.

How does Penumbra compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

GE HealthCare Technologies has higher revenue and earnings than Penumbra. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.41	$2.08B	$4.18	15.24
Penumbra	$1.40B	8.91	$177.69M	$4.34	73.29

In the previous week, GE HealthCare Technologies had 7 more articles in the media than Penumbra. MarketBeat recorded 9 mentions for GE HealthCare Technologies and 2 mentions for Penumbra. GE HealthCare Technologies' average media sentiment score of 1.36 beat Penumbra's score of 0.68 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has a net margin of 11.76% compared to GE HealthCare Technologies' net margin of 9.10%. GE HealthCare Technologies' return on equity of 20.46% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Penumbra	11.76%	10.87%	8.45%

GE HealthCare Technologies presently has a consensus target price of $80.20, suggesting a potential upside of 25.86%. Penumbra has a consensus target price of $361.33, suggesting a potential upside of 13.60%. Given GE HealthCare Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe GE HealthCare Technologies is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by company insiders. Comparatively, 2.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GE HealthCare Technologies has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Summary

GE HealthCare Technologies beats Penumbra on 9 of the 16 factors compared between the two stocks.

How does Penumbra compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Koninklijke Philips has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

In the previous week, Koninklijke Philips and Koninklijke Philips both had 2 articles in the media. Penumbra's average media sentiment score of 0.68 beat Koninklijke Philips' score of 0.50 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has a consensus target price of $361.33, suggesting a potential upside of 13.60%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Penumbra has a net margin of 11.76% compared to Koninklijke Philips' net margin of 5.49%. Koninklijke Philips' return on equity of 13.51% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Penumbra	11.76%	10.87%	8.45%

Koninklijke Philips has higher revenue and earnings than Penumbra. Koninklijke Philips is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.30	$1.01B	$1.17	22.74
Penumbra	$1.40B	8.91	$177.69M	$4.34	73.29

13.7% of Koninklijke Philips shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Penumbra beats Koninklijke Philips on 11 of the 15 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEN vs. The Competition

Export

Metric	Penumbra	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$12.51B	$6.95B	$6.47B	$23.13B
Dividend Yield	N/A	1.25%	2.68%	4.06%
P/E Ratio	73.29	48.65	24.71	31.08
Price / Sales	8.91	46.26	521.51	20.72
Price / Cash	73.79	25.66	27.92	18.65
Price / Book	8.73	7.13	10.82	4.65
Net Income	$177.69M	$159.20M	$3.56B	$1.07B
7 Day Performance	-0.09%	-1.41%	1.67%	-1.04%
1 Month Performance	-3.16%	-1.97%	0.43%	0.18%
1 Year Performance	25.03%	7.94%	32.84%	24.25%

Penumbra Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEN Penumbra	2.5313 of 5 stars	$318.08 +0.6%	$361.33 +13.6%	+23.3%	$12.51B	$1.40B	73.29	4,700
LNTH Lantheus	2.9354 of 5 stars	$106.20 +2.3%	$101.86 -4.1%	+34.1%	$6.76B	$1.54B	25.59	1,193
ITGR Integer	1.9087 of 5 stars	$90.01 -1.0%	$98.71 +9.7%	-23.7%	$3.09B	$1.85B	22.45	11,000	Positive News
MDLN Medline	4.0801 of 5 stars	$34.71 -3.4%	$50.54 +45.6%	N/A	$47.21B	$29.14B	108.47	45,000
GEHC GE HealthCare Technologies	4.9388 of 5 stars	$60.64 -1.5%	$80.21 +32.3%	-14.9%	$28.02B	$20.63B	14.51	54,000	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PEN) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Penumbra (PEN) Competitors